Effect of Vitamin D on All-cause Mortality in Heart Failure Patients (EVITA)

NCT01326650 Phase 4 COMPLETED

Despite significant therapeutic improvements, congestive heart failure (CHF) patients still have a poor prognosis. Currently, 5-year survival rates are only 35-50%. There is an accumulating body of evidence from prospective cohort studies that low circulating 25-hydroxyvitamin D is an independent predictor of all-cause and cardiovascular mortality, respectively. Vitamin D deficiency is prevalent among CHF patients. We hypothesize that vitamin D may improve survival in CHF patients. We therefore aimed to investigate whether vitamin D supplementation reduces mortality and increases event-free survival in end-stage CHF patients.

Details

Lead sponsor	Heart and Diabetes Center North-Rhine Westfalia
Phase	Phase 4
Status	COMPLETED
Enrolment	400
Start date	2010-11
Completion	2016-07

Conditions

• Congestive Heart Failure

Interventions

• Vitamin D
• placebo

Primary outcomes

• Number of participants who died during the intervention — three years
  all-cause mortality (any cause of death) will be assessed

Countries

Germany